Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

Statistically significant linear increase in use of antidementia medications and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

List of Included studies. by Zahra Tajik (20752452)

Subjects:

The search strategy in three databases. by Zahra Tajik (20752452)

Subjects:

A summary of the included study characteristics. by Zahra Tajik (20752452)

Subjects:

NIH score. by Zahra Tajik (20752452)

Subjects:

List of excluded studies. by Zahra Tajik (20752452)

Subjects:

Uganda 2023 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

Subjects:

Uganda 2014 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

Subjects:

Flow diagram illustrating the sequence of procedures executed during one time step defined as tick, each of which represents one week. by Alexandra M. Campbell (3284094)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”

Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Alterations in CBC parameters in albino rats of both genders after 60 days of administration of dimethoate presented in Mean ± S.E.M. and their significance level. by Nida Saleem (17194610)

Subjects:

Alterations in CBC parameters in albino rats of both genders after 30 days of administration of dimethoate presented in Mean ± S.E.M. and their significance level. by Nida Saleem (17194610)

Subjects:

Alterations in CBC parameters in albino rats of both genders after 90 days of administration of dimethoate presented in Mean ± S.E.M. and their significance level. by Nida Saleem (17194610)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects: